CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
![GlobeNewswire](../../../Content/images/providers/GN.png)
CervoMed Inc. (CRVO)
Company Research
Source: GlobeNewswire
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its expected addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective when the U.S. equity markets open on Monday, July 1, 2024, according to the final preliminary list of 2024 additions posted on the FTSE Russell website on June 21st 2024. “Our addition in these widely followed Russell Indexes represents an important achievement for our company and is consistent with the increasing market recognition of the progress we have made in advancing neflamapimod as a potential first-to-market treatment option for patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed. “We look forward to the further heightened awareness of our company that inclusion in the Russell Indexes may bring as we get closer to repo
Show less
Read more
Impact Snapshot
Event Time:
CRVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVO alerts
High impacting CervoMed Inc. news events
Weekly update
A roundup of the hottest topics
CRVO
News
- CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy BodiesGlobeNewswire
- CervoMed to Appoint William Elder as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- CervoMed to Appoint William Elder as Chief Financial OfficerGlobeNewswire
- CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
- CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
CRVO
Analyst Actions
- 4/8/24 - Canaccord Genuity
CRVO
Sec Filings
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- CRVO's page on the SEC website